Vitrolife AB Asset Resilience Ratio
Vitrolife AB asset resilience ratio. Vitrolife AB (VITR) has an Asset Resilience Ratio of 7.27% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Vitrolife AB fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Vitrolife AB (2000–2025)
Asset resilience ratio of Vitrolife AB from 2000 to 2025. This chart shows how Vitrolife AB's Asset Resilience Ratio has changed over time. Read Vitrolife AB balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Vitrolife AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Vitrolife AB.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr809.00 Million | 7.27% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr809.00 Million | 7.27% |
Asset Resilience Insights
- Limited Liquidity: Vitrolife AB maintains only 7.27% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Vitrolife AB Industry Peers by Asset Resilience Ratio
Compare Vitrolife AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Applied BioCode
TW:6598 |
Medical Devices | 9.75% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Radiant Innovation
TWO:3373 |
Medical Devices | 0.82% |
|
Impedimed Ltd
AU:IPD |
Medical Devices | 46.15% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
Vitrolife AB Asset Resilience Ratio by Year (2000–2025)
Vitrolife AB asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for Vitrolife AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.27% | Skr809.00 Million ≈ $87.06 Million |
Skr11.12 Billion ≈ $1.20 Billion |
+0.77pp |
| 2024-12-31 | 6.51% | Skr1.14 Billion ≈ $122.14 Million |
Skr17.45 Billion ≈ $1.88 Billion |
+1.23pp |
| 2023-12-31 | 5.27% | Skr861.00 Million ≈ $92.66 Million |
Skr16.33 Billion ≈ $1.76 Billion |
+2.46pp |
| 2022-12-31 | 2.81% | Skr578.00 Million ≈ $62.20 Million |
Skr20.55 Billion ≈ $2.21 Billion |
-0.43pp |
| 2021-12-31 | 3.24% | Skr630.09 Million ≈ $67.81 Million |
Skr19.43 Billion ≈ $2.09 Billion |
-38.99pp |
| 2020-12-31 | 42.24% | Skr973.57 Million ≈ $104.77 Million |
Skr2.31 Billion ≈ $248.06 Million |
+42.24pp |
| 2018-12-31 | 0.00% | Skr-1.00K ≈ $-107.62 |
Skr1.70 Billion ≈ $182.67 Million |
-0.08pp |
| 2015-12-31 | 0.08% | Skr842.00K ≈ $90.61K |
Skr1.06 Billion ≈ $113.99 Million |
+0.08pp |
| 2014-12-31 | 0.00% | Skr17.00K ≈ $1.83K |
Skr972.48 Million ≈ $104.65 Million |
-0.02pp |
| 2013-12-31 | 0.02% | Skr120.00K ≈ $12.91K |
Skr487.81 Million ≈ $52.50 Million |
-0.04pp |
| 2012-12-31 | 0.06% | Skr289.00K ≈ $31.10K |
Skr462.20 Million ≈ $49.74 Million |
0.00pp |
| 2011-12-31 | 0.06% | Skr295.00K ≈ $31.75K |
Skr466.78 Million ≈ $50.23 Million |
+0.04pp |
| 2010-12-31 | 0.03% | Skr111.00K ≈ $11.95K |
Skr429.39 Million ≈ $46.21 Million |
-0.02pp |
| 2009-12-31 | 0.04% | Skr147.00K ≈ $15.82K |
Skr359.31 Million ≈ $38.67 Million |
-0.01pp |
| 2008-12-31 | 0.05% | Skr180.00K ≈ $19.37K |
Skr342.66 Million ≈ $36.88 Million |
-0.01pp |
| 2007-12-31 | 0.06% | Skr183.00K ≈ $19.69K |
Skr299.46 Million ≈ $32.23 Million |
-10.68pp |
| 2004-12-31 | 10.74% | Skr19.93 Million ≈ $2.15 Million |
Skr185.54 Million ≈ $19.97 Million |
-11.74pp |
| 2001-12-31 | 22.49% | Skr73.77 Million ≈ $7.94 Million |
Skr328.04 Million ≈ $35.30 Million |
-5.98pp |
| 2000-12-31 | 28.46% | Skr49.30 Million ≈ $5.31 Million |
Skr173.22 Million ≈ $18.64 Million |
-- |
About Vitrolife AB
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware … Read more